why choose us

First received: May 05, 2025

Clinical Trial: Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Atopic Dermatitis (Eczema)

Study Type: INTERVENTIONAL


Official Title: A Phase 2, Open Label, 4-Week, Safety Study of Roflumilast Cream 0.05% Administered Once Daily in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Brief Summary: This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).

Read more